Manimaran, V (2016) A Comparative Study on the Efficacy of inhaler Formulation of Fluticasone Propionate with Budesonide and Beclomethasone Dipropionate in Chronic Obstructive Pulmonary Disease. Masters thesis, K.M.College of Pharmacy, Madurai.
|
Text
260702916_manimaran.pdf Download (1MB) | Preview |
Abstract
INTRODUCTION: Chronic obstructive pulmonary disease (COPD)[4] is a respiratory disease characterized by chronic airway inflammation, a decline in lung function over time, and progressive impairment in quality of life. The disease has relatively high prevalence rates worldwide (5–13%) and is mainly caused not only by the inhalation of noxious substances, predominantly cigarette smoking in the Western world, but also by indoor air pollution, particularly in the developing countries. COPD is associated with high mortality and morbidity rates and a high economic and social burden, mainly due to the requirement for substantial and ongoing medical support. COPD is the fourth leading cause of death worldwide and is expected to be the third leading cause by 2030. It is generally believed that despite the availability of both national and international guidelines, COPD remains substantially underdiagnosed and undertreated and is rarely regarded as a health issue of top priority. For many years, smoking cessation has been known to be the single effective intervention for reducing the risk of developing COPD and slowing its progression down .However, recent data from long-term trials have shown that initiating maintenance pharmacological treatment at early stages of the disease, when there is an opportunity to alter the progression of the disease and maximize patient benefit, may alter the clinical course of COPD and can be more effective than at later stages of the disease . Moreover, it has been demonstrated that despite the relative steroid insensitivity of airway inflammation in COPD, the combination of long-acting bronchodilator therapy with inhaled glucocorticosteroids (ICS)is beneficial for patients with severe COPD . Thus, early and optimal pharmacotherapy appears to be fundamental in the management of COPD. AIM OF THE STUDY: The aim of the study is to compare the efficacy and adverse effects of fluticasone propionate with that of budesonide and beclomethasone dipropionate in COPD patients. OBJECTIVE OF THE STUDY: This study is designed to Evaluate the efficacy of fluticasone propionate with that of budesonide and beclomethasone dipropionate in improving lung function, decreasing symptoms and need for rescue medication in COPD A) To establish the effectiveness patient counselling B) To statistically analyze the variables in order to find out the significance DISCUSSION: This study I compares the efficacy of prescribed doses of inhalational steroids in COPD Patients with Fluticasone propionate 100μg twice daily, Budesonide 200 μg twice daily, Beclomethasone dipropionate 200 μg twice daily for four month period . In the present study, the demographic characteristics of the subjects were collected. Out of the 60 COPD patients collected 60% were male and 40% were females. During the study it was observed that most of the populations were from the urban area (60%) are affected as compared to rural area (40%) and this is due to certain aggravating factors like allergens, Dust, air pollution and climatic change. It was observed that 45% of patients coming to the clinic with COPD were between the age group 35-65 years of age when compare to other age groups. Patients in the age group of 46 to 50 are increasing number in this treatment. Out of the 60 patients 36 (60%) were males and 24(40%) were females. This shows that male patients were mostly affected by disorders than female patients. Out of the 60 patients 36 (60%) were from Urban area and 24(40%) were from Rural area . This shows that Urban patients were mostly affected by disorders than Rural patients due to pollution and other environmental factors. In commonly, 30% of Patients know physical illness as the Cause for COPD, 70% of patients Don’t know about physical illness as the Cause for COPD problems In commonly, 30% of Patients know about prevention for COPD eg: Smoking cessation, Improving quality, Occupational therapy, Influenza vaccinations, Pneumococcal vaccination, 70% of patients Don’t know about Cause Prevention for COPD. Out of 60 patients, 20 (33%) were in treatment with Fluticasone Inhalation. Patients showed improvement in COPD with mean value of 26.08%. CONCLUSION: The observational analysis and the laboratory parameters were showed significant improvements in Fluticasone propionate treatment than budesonide and beclomethasone dipropionate. It can be concluded that fluticasone propionate is superior to budesonide and beclomethasone dipropionate in improving lung function, decreasing symptoms and need for rescue medication in COPD. Patient compliance was good with all the three drugs and there is no adverse effect. All the three drugs are well tolerated at doses used in this study.
| Item Type: | Thesis (Masters) |
|---|---|
| Additional Information: | Reg.No:261440057 |
| Uncontrolled Keywords: | A Comparative Study ; Inhaler Formulation ; Fluticasone Propionate ; Budesonide ; Beclomethasone Dipropionate ; Chronic Obstructive Pulmonary Disease |
| Subjects: | PHARMACY > Pharmacy Practice |
| Depositing User: | Ravindran C |
| Date Deposited: | 19 Apr 2018 05:41 |
| Last Modified: | 19 Apr 2018 05:41 |
| URI: | http://repository-tnmgrmu.ac.in/id/eprint/7094 |
Actions (login required)
 |
View Item |
